Upstream Bio Forecast, price target & analysts
Upstream Bio Target price 2025 - Analyst rating & recommendation
Upstream Bio Classifications & Recommendation:
Upstream Bio Price Target
| Target Price | $55.00 |
| Price | $11.36 |
| Potential |
384.16%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target Upstream Bio 2026 .
The average Upstream Bio target price is $55.00.
This is
384.16%
register free of charge
$75.00
560.21%
register free of charge
$35.00
208.10%
register free of charge
|
|
| A rating was issued by 4 analysts: 4 Analysts recommend Upstream Bio to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Upstream Bio stock has an average upside potential 2026 of
384.16%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.37 | 1.62 |
| 0.42% | 31.55% | |
| EBITDA Margin | -3,277.64% | -9,228.09% |
| 94.78% | 181.55% | |
| Net Margin | -3,223.63% | -8,411.14% |
| 100.53% | 160.92% |
4 Analysts have issued a sales forecast Upstream Bio 2025 . The average Upstream Bio sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Upstream Bio 2025 . The average Upstream Bio EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Upstream Bio 2025 . The average Upstream Bio net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.49 | -2.54 |
| 98.67% | 70.47% | |
| P/E | negative | |
| EV/Sales | 110.78 |
1 Analysts have issued a Upstream Bio forecast for earnings per share. The average Upstream Bio EPS is
This results in the following potential growth metrics and future valuations:
Current Upstream Bio Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| William Blair |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 05 2024 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 05 2024 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Nov 05 2024 |
|
Locked
William Blair:
Locked
➜
Locked
|
Nov 05 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
